Posted on September 10th, 2014
by James Joyce
Are pandemic viral pathogens establishing a global foothold? At present, the deadliest Ebola virus outbreak in history continues to burn through Africa. Japan is experiencing its first Dengue outbreak in 70 years, and in the U.S., twelve states have just reported clusters of Enterovirus D68 infection. Additionally, since the first documented occurrence of Chikungunya virus in the Americas late last year, 31 states have now reported infections from this debilitating viral pathogen. Worldwide outbreaks of viral pathogens will continue to be fueled by urbanization, improvements in mass transportation, global warming, and the continued evolution of new viral strains and species.
In my inaugural Chairman’s blog post, I will outline the Aethlon Medical strategy to combat chronic and emerging viral threats. In future blogs, I look forward to discussing our role in cancer immunotherapy as well as the diagnostic endeavors being advanced by our Exosome Sciences subsidiary.
Specific to viral threats, we recognized early on that there would be a continued need for a therapeutic strategy that could address antiviral drug resistance, which often occurs in chronic viral pathogens such as HIV and Hepatitis C virus (HCV). We also recognized that the vast majority of acute viral pathogens (including bioterror and pandemic threats) were not addressed with corresponding drugs or vaccines. In response, we created the Aethlon Hemopurifier® to address these unmet medical needs.
The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes, which suppress the immune system and contribute to the spread of metastasis in cancer patients. We are now preparing to launch the first FDA approved study of Hemopurifier® therapy in the United States. Previously, we conducted studies of Hemopurifier® therapy with success in HIV and HCV-infected individuals at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India.
The goal of our FDA cleared study is to collect safety data that will allow us to advance the Hemopurifier® as a treatment against chronic viral indications and as a broad-spectrum countermeasure against emerging pandemic threats.
So, beyond our previous treatment experience overseas, you might ask what evidence do we have that our Hemopurifier® could address emerging pandemic threats. Well, previously conducted in vitro studies have verified Hemopurifier® capture of ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading government and non- government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR).
Based on this collection of data, we are confident that the Aethlon Hemopurifier® is the most advanced broad-spectrum countermeasure against viral pathogens. We hope you follow our clinical efforts to advance this therapeutic technology into the marketplace. Our mission is simply to save lives.
Forward Looking Statements
This blog contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary. will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.